Compare iShares Core MSCI EAFE ETF (IEFA) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Moderna, Inc. — how do they compare? iShares Core MSCI EAFE ETF trades at $101.22, while Moderna, Inc. trades at $63.92 (market cap $25.42B). The key difference: iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| IEFA | MRNA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $101.22 | $81.80 |
52-Week Low | $84.72 | $22.36 |
Market Cap | — | $25.42B |
Enterprise Value | — | $21.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $101.02, up 0.39% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on developed international equities excluding the U.S. and Canada, offering diversification benefits amid U.S. market concentration risks. Recent news highlights its role in income strategies and cost efficiency compared to peers like EFA.
The outlook remains positive for long-term investors seeking international exposure and dividend income, though near-term risks include potential pullbacks from overbought conditions and developed market central bank policy shifts. The fund's low expense ratio and defensive characteristics support its appeal in volatile markets.
Moderna (MRNA) trades at $63.65, up 5.09% on the day, with a bullish technical signal from moving averages and recent FDA approval of its mRNA flu vaccine mFLUSIVA for adults 50+. Despite negative net income margins and declining revenue since 2022, the company beat Q2 2026 EPS estimates and maintains a diversified pipeline in flu, oncology, and rare diseases. Cash flow improved in 2025 with positive net cash flow of $668 million.
The outlook hinges on pipeline execution beyond COVID-19, with growth opportunities in new vaccine approvals but significant risks from persistent losses and competitive pressures. Analyst consensus is cautious with a hold-heavy rating and $54.33 price target below the current price, indicating skepticism about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
